Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov128610.25208/vdv1286REVIEWSОБЗОР ЛИТЕРАТУРЫReview ArticleLong-wavelength ultraviolet A (UVA-1) phototherapy for the treatment of patients with atopic dermatitisУльтрафиолетовая терапия дальнего длинноволнового диапазона (УФА-1-терапия) в лечении больных атопическим дерматитомhttps://orcid.org/0000-0003-3805-84893604-6491KaramovaA. E.КарамоваА. Э.
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

karamova@cnikvi.ruhttps://orcid.org/0000-0002-9688-27273385-4723ChikinV. V.ЧикинВ. В.
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н

chikin@cnikvi.ruhttps://orcid.org/0000-0002-7625-05038771-4990KubanovA. A.КубановА. А.
Russian Federation

MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

д.м.н., профессор, член-корреспондент РАН

alex@cnikvi.ruhttps://orcid.org/0000-0003-4952-0800DavletbaevaL. K.ДавлетбаеваЛ. Х.
Russian Federation
lesya-gl@mail.ruState Research Center of Dermatovenereology and CosmetologyГосударственный научный центр дерматовенерологии и косметологии2312202197526370410202128102021Copyright ©; 2021, Karamova A.E., Chikin V.V., Kubanov A.A., Davletbaeva L.K.Copyright ©; 2021, Карамова А.Э., Чикин В.В., Кубанов А.А., Давлетбаева Л.Х.2021Karamova A.E., Chikin V.V., Kubanov A.A., Davletbaeva L.K.Карамова А.Э., Чикин В.В., Кубанов А.А., Давлетбаева Л.Х.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/1286

One of the methods of therapy for atopic dermatitis is long-wavelength ultraviolet therapy A (UVA-1- therapy). This review aims to provide the mechanisms of action of UVA-1-therapy an overview about the effectiveness of UVA-1-therapy in patients with atopic dermatitis taking into account factors that can affect the effectiveness of treatment — radiation dose, skin phototype of patients, concomitant drug therapy. The available data on a decrease in the severity of atopic dermatitis as a result of the course of UVA-1-therapy and on a decrease in the severity of itching in patients are presented. The data on the rate of onset of the therapeutic effect of UVA-1-therapy and the duration of its maintenance are considered. The safety of UVA-1-therapy is discussed, and the most frequent undesirable effects — a feeling of warmth, fever, itching, hyperpigmentation, are given. The possibility of developing side effects requiring discontinuation of treatment is assessed. The data obtained indicate the effectiveness and safety of the UFA-1-radiation in the treatment of patients with moderate-to-severe atopic dermatitis.

Одним из методов терапии атопического дерматита является общая ультрафиолетовая терапия дальнего длинноволнового диапазона (УФА-1-терапия). В обзоре литературы рассматриваются механизмы терапевтического действия УФА-1-терапии. Приведен анализ эффективности УФА-1-терапии больных атопическим дерматитом с учетом факторов, которые могут влиять на эффективность лечения, — дозы излучения, фототип кожи пациентов, проведение сопутствующей лекарственной терапии. Представлены имеющиеся данные об уменьшении степени тяжести атопического дерматита в результате курса УФА-1-терапии и об уменьшении у пациентов выраженности зуда. Рассмотрены данные о скорости наступления терапевтического эффекта УФА-1-терапии и продолжительности его сохранения. Обсуждается безопасность УФА-1-терапии, приводятся наиболее частые нежелательные эффекты — ощущение тепла, жара, зуд, гиперпигментация. Оценивается возможность развития нежелательных явлений, требующих прекращения лечения. Полученные данные свидетельствуют об эффективности и безопасности использования УФА-1-терапии для лечения больных атопическим дерматитом средней и тяжелой степени тяжести.

atopic dermatitisphototherapyUVA-1-therapyefficacysafetyатопический дерматитобщая ультрафиолетовая терапия дальнего длинноволнового диапазонаУФА-1-терапияэффективностьбезопасностьThe work was done through financing at the place of work of the authors.Работа выполнена за счет финансирования по месту работы авторов.Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–349. doi: 10.1016/j.jaci.2016.06.010Biedermann T, Skabytska Y, Kaesler S, Volz T. Regulation of T cell immunity in atopic dermatitis by microbes: The Yin and Yang of cutaneous inflammation. Front Immunol. 2015;13;6:353. doi: 10.3389/fimmu.2015.00353Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: 10.1016/S0140-6736(20)31286-1Luger T, Amagai M, Dreno B, Dagnelie MA, Liao W, Kabashima K, et al. Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents. J Dermatol Sci. 2021;102(3):142–157. doi: 10.1016/j.jdermsci.2021.04.007Leung DY, Bhan AK, Schneeberger EE, Geha RS. Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies. J Allergy Clin Immunol. 1983;71(1 Pt 1):47–56. doi: 10.1016/0091-6749(83)90546-8Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769–779. doi: 10.1016/j.jaci.2014.08.008Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest. 1994;94:870–876. doi: 10.1172/JCI117408Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol. 1996;98(1):225–231. doi: 10.1016/s0091-6749(96)70246-4Czarnowicki T, Krueger JG, Guttman-Yassky E. Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. J Allergy Clin Immunol Pract. 2014;2(4):371–379. doi: 10.1016/j.jaip.2014.03.006Oliva M, Renert-Yuval Y, Guttman-Yassky E. The ‘omics’ revolution: redefining the understanding and treatment of allergic skin diseases. Curr Opin Allergy Clin Immunol. 2016;16(5):469-476.doi: 10.1097/ACI.0000000000000306Gittler JK, Shemer A, Suárez-Fariñas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344–1354. doi: 10.1016/j.jaci.2012.07.012Dhingra N, Guttman-Yassky E. A possible role for IL-17A in establishing Th2 inflammation in murine models of atopic dermatitis. J Invest Dermatol. 2014;134(8):2071–2074. doi: 10.1038/jid.2014.141Thepen T, Langeveld-Wildschut EG, Bihari IC, van Wichen DF, van Reijsen FC, Mudde GC, et al. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J Allergy Clin Immunol. 1996;97(3):828–837. doi: 10.1016/s0091-6749(96)80161-8Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol. 2020;124(1):36–43. doi: 10.1016/j.anai.2019.10.008Danso MO, van Drongelen V, Mulder A, van Esch J, Scott H, van Smeden J, et al. TNF-alpha and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol. 2014;134(7):1941–1950. doi: 10.1038/jid.2014.83Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126(3):332–337. doi: 10.1016/j.clim.2007.11.006Gutowska-Owsiak D, Schaupp AL, Salimi M, Selvakumar TA, McPherson T, Taylor S, et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol. 2012;21(2):104–110. doi: 10.1111/j.1600-0625.2011.01412.xHowell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, Debenedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150–155. doi: 10.1016/j.jaci.2007.04.031Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138(2):350–358. doi: 10.1016/j.jaci.2016.06.002Sehra S, Yao Y, Howell MD, Nguyen ET, Kansas GS, Leung DY, et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol. 2010;184(6):3186–3190. doi: 10.4049/jimmunol.0901860Gutowska-Owsiak D, Schaupp AL, Salimi M, Taylor S, Ogg GS. Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br J Dermatol. 2011;165(3):492–498. doi: 10.1111/j.1365-2133.2011.10400.xOuyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71–109. doi: 10.1146/annurev-immunol-031210-101312Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170–181. doi: 10.1038/nri2711Brandt EB, Sivaprasad U. Th2 Cytokines and Atopic Dermatitis. J Clin Cell Immunol. 2011:2(3):110. doi: 10.4172/2155-9899.1000110Darling AR, Freyschmidt EJ, Burton OT, Koleoglou KJ, Oyoshi MK, Oettgen HC. IL-10 suppresses IL-17-mediated dermal inflammation and reduces the systemic burden of vaccinia virus in a mouse model of eczema vaccinatum. Clin Immunol. 2014;150(2):153–160. doi:10.1016/j.clim.2013.11.010Niwa Y. Elevated RANTES levels in plasma or skin and decreased plasma IL-10 levels in subsets of patients with severe atopic dermatitis. Arch Dermatol. 2000;136(1):125–126. doi: 10.1001/archderm.136.1.125Seneviratne SL, Jones L, Bailey AS, Black AP, Ogg GS. Severe atopic dermatitis is associated with a reduced frequency of IL-10 producing allergen-specific CD4+ T cells. Clin Exp Dermatol. 2006;31(5):689–694. doi: 10.1111/j.1365-2230.2006.02172.xDunstan JA, Hale J, Breckler L, Lehmann H, Weston S, Richmond P, et al. Atopic dermatitis in young children is associated with impaired interleukin-10 and interferon-gamma responses to allergens, vaccines and colonizing skin and gut bacteria. Clin Exp Allergy. 2005;35(10):1309–1317. doi: 10.1111/j.1365-2222.2005.02348.xOh SH, Park CO, Wu WH, Kim JY, Jin S, Byamba D, et al. Corticotropin-releasing hormone downregulates IL-10 production by adaptive forkhead box protein 3-negative regulatory T cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2012;129(1):151–159. doi: 10.1016/j.jaci.2011.09.008York NR, Jacobe HT. UVA1 phototherapy: a review of mechanism and therapeutic application. Int J Dermatol. 2010;49(6):623–630. doi: 10.1111/j.1365-4632.2009.04427.xSinger S, Berneburg M. Phototherapie. J Dtsch Dermatol Ges. 2018;16(9):1120–1131. doi: 10.1111/ddg.13646_gVieyra-Garcia PA, Wolf P. A deep dive into UV-based phototherapy: Mechanisms of action and emerging molecular targets in inflammation and cancer. Pharmacol Ther. 2021;222:107784. doi: 10.1016/j.pharmthera.2020.107784Mutzhas MF, Holzle E, Hofmann C, Plewig G. A new apparatus with high radiation energy between 320-460 nm: physical description and dermatological applications. J Invest Dermatol. 1981;76(1):42–47. doi: 10.1111/1523-1747.ep12524813Gambichler T, Terras S, Kreuter A. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: Facts and controversies. Clin Dermatol. 2013;31(4):438–454. doi: 10.1016/j.clindermatol.2013.01.011Plewig G, Hofmann C, Braun-Falco O, Nath G, Kreitmair A. A new apparatus for the delivery of high intensity UVA and UVA+UVB irradiation, and some dermatological applications. Br J Dermatol. 1978;98(1):15–24. doi: 10.1111/j.1365-2133.1978.tb07328.xKrutmann J. Phototherapy for atopic dermatitis. Clin Exp Dermatol. 2000;25(7):552–558. doi: 10.1046/j.1365-2230.2000.00700.xGambichler T, Majert J, Pljakic A, Rooms I, Wolf P. Determination of the minimal erythema dose for ultraviolet A1 radiation. Br J Dermatol. 2017;177(1):238–244. doi: 10.1111/bjd.15245Grabbe J, Welker P, Humke S, Grewe M, Schöpf E, Henz BM, Krutmann J. High-dose ultraviolet A1 (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. J Invest Dermatol. 1996;107(3):419–422. doi: 10.1111/1523-1747.ep12363402Besaratinia A, Kim SI, Bates SE, Pfeifer GP. Riboflavin activated by ultraviolet A1 irradiation induces oxidative DNA damage-mediated mutations inhibited by vitamin C. Proc Natl Acad Sci USA. 2007;104(14):5953–5958. doi: 10.1073/pnas.0610534104Godar DE. UVA1 radiation triggers two different final apoptotic pathways. J Invest Dermatol. 1999;112(1):3–12. doi: 10.1046/j.1523-1747.1999.00474.xGuhl S, Hartmann K, Tapkenhinrichs S, Smorodchenko A, Grützkau A, Henz BM, Zuberbier T. Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells. J Invest Dermatol. 2003;121(4):837–844. doi: 10.1046/j.1523-1747.2003.12480.xНовиков В.Е., Левченкова О.С. Митохондриальные мишени для фармакологической регуляции адаптации клетки к воздействию гипоксии. Обзоры по клинической фармакологии и лекарственной терапии. 2014;12(2):28–35. [Novikov VE, Levchenkova OS. Mitochondrial targets for pharmacological regulation of cell adaptation to hypoxia. Reviews on Clinical Pharmacology and Drug Therapy. 2014;12(2):28–35 (In Russ.)]Godar DE. Preprogrammed and programmed cell death mechanisms of apoptosis: UV-induced immediate and delayed apoptosis. Photochem Photobiol. 1996;63(6):825–830. doi: 10.1111/j.1751-1097.1996.tb09638.xTyrrell R.M. Ultraviolet radiation and free radical damage to skin. Biochem Soc Symp. 1995;61:47–53. doi: 10.1042/bss0610047Skov L, Hansen H, Allen M, Villadsen L, Norval M, Barker JN, et al. Contrasting effects of ultraviolet A1 and ultraviolet B exposure on the induction of tumour necrosis factor-alpha in human skin. Br J Dermatol. 1998;138(2):216–220. doi: 10.1046/j.1365-2133.1998.02063.xKrutmann J, Grewe M. Involvement of cytokines, DNA damage, and reactive oxygen intermediates in ultraviolet radiation-induced modulation of intercellular adhesion molecule-1 expression. J Invest Dermatol. 1995;105(1 Suppl):67S–70S. doi: 10.1111/1523-1747.ep12316095Szegedi A, Simics E, Aleksza M, Horkay I, Gaál K, Sipka S, et al. Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44(7):925–931. doi: 10.1093/rheumatology/keh643Grewe M, Gyufko K, Krutmann J. Interleukin-10 production by cultured human keratinocytes: regulation by ultraviolet B and ultraviolet A1 radiation. J Invest Dermatol. 1995;104(1):3–6. doi: 10.1111/1523-1747.ep12613446Gambichler T, Othlinghaus N, Tomi NS, Holland-Letz T, Boms S, Skrygan M, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol 2009;160(3):652–658. doi: 10.1111/j.1365-2133.2008.08984.xTzaneva S, Kittler H, Holzer G, Reljic D, Weber M, Hönigsmann H, Tanew A. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: A randomized crossover trial. Br J Dermatol. 2010;162(3):655–660. doi: 10.1111/j.1365-2133.2009.09514.xvon Kobyletzki G, Pieck C, Hoffmann K, Freitag M, Altmeyer P. Medium-dose UVA1 cold-light phototherapy in the treatment of severe atopic dermatitis. J Am Acad Dermatol. 1999;41(6):931–937. doi: 10.1016/s0190-9622(99)70249-5von Kobyletzki G, Freitag M, Herde M, Höxtermann S, Stücker M, Hoffmann K, Altmeyer P. Phototherapie bei schwerer atopischer Dermatitis. Vergleich zwischen herkömmlicher UVA1-Therapie, UVA1-Kaltlicht- und kombinierter UVA-UVB-Therapie. Hautarzt. 1999;50(1):27–33. doi: 10.1007/s001050050860Krutmann J, Czech W, Diepgen T, Niedner R, Kapp A, Schöpf E. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol. 1992;26(2 Pt 1):225–230. doi: 10.1016/0190-9622(92)70031-aKrutmann J, Diepgen TL, Luger TA, Grabbe S, Meffert H, Sönnichsen N, et al. High-dose UVA1 therapy for atopic dermatitis: Results of a multicenter trial. J Am Acad Dermatol. 1998;38(4):589–593. doi: 10.1016/s0190-9622(98)70123-9Osmola-Mańkowska A, Polańska A, Silny W, Żaba R, Adamski Z, Dańczak-Pazdrowska A. Topical tacrolimus vs medium-dose ultraviolet A1 phototherapy in the treatment of atopic dermatitis — a preliminary study in relation to parameters of the epidermal barrier function and high-frequency ultrasonography. Eur Rev Med Pharmacol Sci. 2014;18(24):3927–3934.Tzaneva S, Seeber A, Schwaiger M, Hönigsmann H, Tanew A. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol. 2001;45(4):503–507. doi: 10.1067/mjd.2001.114743Pacifico A, Iacovelli P, Damiani G, Ferraro C, Cazzaniga S, Conic RR, et al. 'High dose' vs. 'medium dose' UVA1 phototherapy in italian patients with severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2019;33(4):718–724. doi: 10.1111/jdv.15362Kowalzick L, Kleinheinz A, Weichenthal M, Neuber K, Köhler I, Grosch J, et al. Low dose versus medium dose UV-A1 treatment in severe atopic dermatitis. Acta Derm Venereol. 1995; 75 (1): 43–45. doi: 10.2340/00015555754345Dittmar HC, Pflieger D, Schopf E, Simon JC. UVA1-Phototherapie. Pilotstudie zur Dosisfindung bei der bei akut exazerbierten atopischen Dermatitis. Hautarzt. 2001;52(5):423–427. doi: 10.1007/s001050051336Бакулев А.Л., Платонова А.Н. Отдаленные результаты применения УФА-1-терапии в комплексном лечении атопического дерматита. Бюллетень медицинских интернет-конференций (ISSN 2224‐6150) 2013;3(6):961–963. [Bakulev AL, Platonova AN. Long-term results of usage of UVA-1-therapy in complex treatment of atopic dermatitis. Bulletin of Medical Internet Conferences. 2013;3(6):961–963 (In Russ.)]Majoie IM, Oldhoff JM, van Weelden H, Laaper-Ertmann M, Bousema MT, Sigurdsson V, et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2009;60(1):77–84. doi: 10.1016/j.jaad.2008.08.048Legat FJ, Hofer A, Brabek E, Quehenberger F, Kerl H, Wolf P. Narrowband UV-B vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis. Arch Dermatol. 2003;139:223–224. doi: 10.1001/archderm.139.2.223Олисова О.Ю., Владимиров В.В., Мураховская Е.К. Фототерапия атопического дерматита УФА-лучами 370 нм. Российский журнал кожных и венерических болезней. 2013;6:22–27. [Olisova OYu, Vladimirov VV, Murakhovskaya EK. UVA 370 nm phototherapy of atopic dermatitis. Russian Journal of Skin and Venereal Diseases. 2013;6:22–27 (In Russ.)]Abeck D, Schmidt T, Fesq H, Strom K, Mempel M, Brockow K, et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol. 2000;42(2 Pt 1):254–257. doi: 10.1016/S0190-9622(00)90134-8Gambichler T, Kreuter A, Tomi NS, Othlinghaus N, Altmeyer P, Skrygan M. Gene expression of cytokines in atopic eczema before and after ultraviolet A1 phototherapy. Br J Dermatol. 2008;158(5):1117–1120. doi: 10.1111/j.1365-2133.2008.08498.xBogaczewicz J, Malinowska K, Sysa-Jedrzejowska A, Wozniacka A. Medium-dose ultraviolet A1 phototherapy improves SCORAD index and increases mRNA expression of interleukin-4 without direct effect on human β defensin-1, interleukin-10, and interleukin-31. Int J Dermatol. 2016;55(7):e380–e385. doi: 10.1111/ijd.13213Bogaczewicz J, Malinowska K, Sysa-Jedrzejowska A, Wozniacka A. Medium-dose ultraviolet A1 phototherapy and mRNA expression of TSLP, TARC, IL-5, and IL-13 in acute skin lesions in atopic dermatitis. Int J Dermatol. 2016;55(8):856–863. doi: 10.1111/ijd.12992Malinowska K, Wozniacka A, Bogaczewicz J. The impact of medium dose UVA1 phototherapy on pruritus, DLQI and SCORAD index in patients with atopic dermatitis. Postepy Dermatol Alergol. 2020;37(6):962–967. doi: 10.5114/ada.2019.88465Park JB, Jang JY, Kwon DI, Seong SH, Suh KS, Jang MS. The effectiveness of high-dose ultraviolet A-1 phototherapy for acute exacerbation of atopic dermatitis in Asians. Photodermatol Photoimmunol Photomed. 2020;36(4):263–270. doi: 10.1111/phpp.12546Авдиенко И.Н., Кубанов А.А. Эффективность дальней длинноволновой ультрафиолетовой терапии у больных атопическим дерматитом. Вестник дерматологии и венерологии. 2009;3:61–63. [Avdienko IN, Kubanov AA. Efficiency of long-wave ultraviolet therapy in patients with atopic dermatitis. Vestnik Dermatologii i Venerologii. 2009;3:61–63 (In Russ.)]Tajima T, Ibe M, Matsushita T, Kamide R. A variety of skin responses to ultraviolet irradiation in patients with atopic dermatitis. J Dermatol Sci. 1998;17(2):101–107. doi: 10.1016/s0923-1811(97)00080-7Valbuena Mesa MC, Nova Villanueva JA, Sánchez Vanegas G. Minimal erythema dose: Correlation with Fitzpatrick skin type and concordance between methods of erythema assessment in a patient sample in Colombia. Actas Dermosifiliogr (Engl Ed). 2020;111(5):390–397. doi: 10.1016/j.ad.2019.12.003Welti M, Ramelyte E, Dummer R, Imhof L. Evaluation of the minimal erythema dose for UVB and UVA in context of skin phototype and nature of photodermatosis. Photodermatol Photoimmunol Photomed. 2020;36(3):200–207. doi: 10.1111/phpp.12537Beattie PE, Dawe RS, Ferguson J, Ibbotson SH. Dose-response and time-course characteristics of UV-A1 erythema. Arch Dermatol. 2005;141(12):1549–1555. doi: 10.1001/archderm.141.12.1549Kroft EB, Berkhof NJ, van de Kerkhof PC, Gerritsen RM, de Jong EM. Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol. 2008;59(6):1017–1030. doi: 10.1016/j.jaad.2008.07.042Gambichler T. Management of atopic dermatitis using photo(chemo) therapy. Arch Dermatol Res. 2009;301(3):197–203. doi: 10.1007/s00403-008-0923-5Dawe RS. Ultraviolet A1 phototherapy. Br J Dermatol. 2003;148(4):626–637. doi: 10.1046/j.1365-2133.2003.05261.xGambichler T, Al-Muhammadi R, Boms S. Immunologically mediated photodermatoses: diagnosis and treatment. Am J Clin Dermatol. 2009;10(3):169–180. doi: 10.2165/00128071-200910030-00003ten Berge O, van Weelden H, Bruijnzeel-Koomen CA, de Bruin-Weller MS, Sigurdsson V. Throwing a light on photosensitivity in atopic dermatitis: a retrospective study. Am J Clin Dermatol. 2009;10(2):119–123. doi: 10.2165/00128071-200910020-00004Schempp CM, Effinger T, Czech W, Krutmann J, Simon JC, Schöpf E. Charakterisierung von Non-Respondern bei der hochdosierten UVA1-Therapie der akut exazerbierten Atopischen Dermatitis. Hautarzt. 1997;48(2):94–99. doi: 10.1007/s001050050552Brem R, Daehn I, Karran P. Efficient DNA interstrand crosslinking by 6-thioguanine and UVA radiation. DNA Repair (Amst). 2011;10(8):869–876. doi: 10.1016/j.dnarep.2011.05.010Brem R, Karran P. Multiple forms of DNA damage caused by UVA photoactivation of DNA 6-thioguanine. Photochem Photobiol. 2011;88(1):5–13. doi: 10.1111/j.1751-1097.2011.01043.xAmber T, Tabassum S. Cyclosporin in dermatology: A practical compendium. Dermatol Ther. 2020;33(6):e13934. doi: 10.1111/dth.13934